WEBCAST FAQ MEDIA CENTRE SITE MAP CONTACT US

CD-ROM

Back to the PAG

Presentation type Track Abstract category Text
Late breakers only  
 

TrackAbstract codesAbstract Categories
AA001 - 009 HIV diversity and epidemiology
AA010 - 012 HIV superinfections
AA013 Bioinformatics analysis of viral diversity in natural history
AA014 Bioinformatic analysis in drug resistance
AA015 - 016 HIV Pathogenesis/Immune Function and Dysfunction
AA017 Innate immunity responses and function in natural history of HIV infection
AA018 Virus-specific cellular immunity
AA019 - 022 Mucosal immunity/defenses: responses and dysfunction
AA023 - 027 Correlates of immune protection
AA028 Mechanisms of T cell depletion and dysfunction
AA029 HIV Pathogenesis/Latency and Viral Reservoirs
AA030 - 031 HIV tropism, dynamics and fitness
AA032 - 034 Host genetics of resistance and susceptibility
AA036 - 040 Transmission and Early Infection
AA041 Animal models of transmission, disease resistance and progression
AA042 - 044 Mucosal transmission
AA045 - 046 Mother to child transmission
AA047 Novel Treatment and Prevention Strategies
AA048 Preclinical development of microbicides
AA049 - 060 Nucleic acid based HIV and SIV therapies
AA061 - 062 Antibody based vaccines
AA063 - 066 Cellular immunity based vaccines
AA067 - 073 Novel vectors and strategies
AA074 - 077 Animal Models
AA078 Viral determinants of SIV pathogenesis
AA079 - 080 Non pathogenic models of SIV
AA081 Novel animal models for vaccine and inhibitor development
AA082 HIV-1 and HIV-2 co-infections
AA083 - 084 Mycobacteria and TB
AA085 - 090 Malaria
AA091 - 096 Diagnostic Tools for the Immunological and Virological Monitoring of HIV Infection
AA097 - 105 Novel assays of immune responses
AA106 - 113 Track B - Clinical Sciences
BB001 - 002 Acute and early infection
BB003 - 004 Disease burden – morbidity/mortality
BB005 - 008 Ageing
BB009 Non-AIDS related co-morbidities (e.g. diabetes, hypertension etc)
BB010 - 012 Impact of nutrition
BB013 - 016 HIV-2
BB017 - 019 New monitoring strategies including rapid tests
BB020 - 029 Viral resistance testing in clinical trials and practice
BB030 Viral fitness and tropism assays, utility and application in clinical practice
BB031 - 036 Opportunistic infections (excluding mycobacterial)
BB037 - 042 Tuberculosis
BB043 Other bacterial infections and malaria and parasitic infections
BB044 - 052 Hepatitis co-infections: (including HBV, HCV)
BB053 - 057 Sexually transmitted infections (STI)
BB058 - 059 Prophylaxis of HIV associated infections; vaccines e.g. pneumococcal, hepatitis and HPV, co-trimoxazole prophylaxis and IPT
BB060 - 061 Neurologic and psychiatric manifestations, including neurocognitive disorders
BB062 - 064 Immune reconstitution disorders / IRIS
BB065 - 067 AIDS related malignancies (KS, lymphoma, cervical and anal carcinoma) including HHV8 infection
BB068 - 069 Non-AIDS related malignancies
BB070 - 073 Clinical trials
BB074 - 075 Cohort studies
BB076 Acute and early infection and management of patients with acquired viral resistance
BB077 - 078 Pharmacogenomics
BB079 - 085 When to start therapy
BB086 - 114 First line therapy
BB088 - 123 Simplification strategies (induction/maintenance and use of bPI monotherapy)
BB094 - 128 Switch studies
BB095 - 096 Therapy for the heavily pre-treated patient
BB097 - 100 Antiretroviral Therapies (strategic categories apply to resource rich and constrained settings) in Children and Adolescents
BB101 Diagnosis of HIV disease
BB102 - 105 Pharmacology, pharmacokinetics, drug formulations
BB106 - 109 Antiretroviral therapy,clinical trials and cohorts
BB115 - 118 Management of late presenters
BB129 Complications of Anti-Retroviral Therapy and Adherence in Adults and Children
CC001 - 004 Other adverse reactions and complications of ARV therapy
CC005 - 024 Adherence in adults
CC025 - 027 Adherence in children and adolescents
CC028 - 030 Other complications
CC031 - 036 Other Therapies
CC037 Complementary and traditional medicines and the role of traditional healers in therapy
CC038 - 039 Track C: Epidemiology and Prevention Sciences
CC040 - 041 Natural history, progression and survival
CC042 Epidemiology of HIV in people who use drugs
CC043 - 047 Epidemiology of sexually transmitted infections (STI) and HIV
CC048 - 049 Methodological Issues and Capacity-Building in Epidemiology and Prevention Research
CC050 - 056 Research designs in epidemiology
CC057 - 058 Ethical issues in epidemiological research
CC059 - 060 Measuring and modelling the impact of the HIV epidemic
CC061 - 063 Measuring and modelling the effect and impact of PMTCT
CC064 - 068 Measuring and modelling the effect and impact of other HIV prevention interventions
CC069 - 074 New HIV testing and diagnostic strategies
CC075 - 078 Estimating the size of HIV-infected and most at risk population
CC079 - 090 Estimating the need for HIV treatment
CC091 - 094 HIV Surveillance, Monitoring and Evaluation
CC095 - 099 Paediatric surveillance of HIV
CC100 - 103 Surveillance of HIV (Youth and Adults)
CC104 - 119 Behavioural surveillance
DD001 - 015 Surveillance systems and methods
DD016 - 019 Population-based surveys with HIV testing
DD020 - 030 Monitoring and evaluation of HIV prevention, care and treatment
DD031 - 049 Monitoring and evaluation (other)
DD050 - 184 Prevention of mother-to-child transmission
DD074 - 094 Male and female condoms and other physical barriers
DD095 - 104 Harm reduction, including reduction of unsafe injecting and other approaches
DD105 - 115 Blood, organ and tissue safety and nosocomial transmission
DD116 - 122 Male circumcision
DD123 - 133 STI prevention and control
DD134 - 135 Pre-exposure and post-exposure prophylaxis
DD136 Microbicides
DD137 - 138 Antiretroviral treatment of people living with HIV for prevention
DD139 Approaches to counselling and testing in children and caregivers
DD140 - 147 HIV counselling, testing and diagnostic strategies
DD148 - 159 Prevention in institutional settings e.g. workplace, school, prison, military
DD160 Prevention for the general population
DD161 Prevention addressing gender inequalities
DD162 - 166 Prevention for people who use drugs
DD167 - 185 Prevention for men who have sex with men (MSM)
DD174 - 183 Prevention for people living with HIV

Back to the Programme-at-a-Glance


Contact Us | Site map © 2009 International AIDS Society